# US 2013/0281303 A1 · Comprehensive monoclonal antibody generation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281303 A1
- Document ID: US20130281303A1
- Status: Published application
- Kind: A1
- Application number: 13/977,193
- Filed: 2011-12-28
- Published: 2013-10-24
- Earliest claimed: 2011-12-28
- Assignees: BioAtla, Inc.
- Inventors: Jay M. Short
- Web page: https://patentgrep.com/patent/US20130281303A1

## CPC

- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/005: {constructed by phage libraries}
- G01N 33/5052: {involving B-cells}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/6857: {Antibody fragments}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

## Claims

### Claim 1

A method of generating and identifying a recombinant antibody that binds at least one target antigen comprising:
a) screening B cells to generate a B cell library enriched in B cells capable of binding to the at least one target antigen;
b) amplifying cDNA obtained from mRNA expressed in the B cell library to prepare an immunoglobulin library comprising VH and VL domains;
c) generating antibodies from the VH and VL domains whereby the antibodies comprise light chain/heavy chain combinations and whereby the number of combinations generated is more than the number of B cells in the enriched B cell library; and
d) screening the antibodies with the at least one target antigen to identify a subset of antibodies capable of binding to the at least one target antigen;
whereby a recombinant antibody that binds at least one target antigen is generated and identified.

### Claim 2 (depends on 1)

The method of claim 1, wherein the B cell library contains at least 103 B cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the B cell library contains at least 105 B cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the B cell library contains at least 106 B cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the B cell library contains at least 107 B cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the B cell library contains at least 108 B cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the a) screening is selected from the group consisting of fluorescence activated cell sorting (FACS) and panning.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one target antigen is a single target antigen.

### Claim 9 (depends on 1)

The method of claim 1, wherein the at least one target antigen is at least two target antigens and the a) screening is screening for B cells capable of binding to the at least two target antigens.

### Claim 10 (depends on 9)

The method of claim 9, wherein the at least two target antigens are two epitopes on a single target molecule.

### Claim 11 (depends on 1)

The method of claim 1, wherein the B cells are B cells from a non-human host.

### Claim 12 (depends on 11)

The method of claim 11, wherein the non-human host is immunized with a target antigen.

### Claim 13 (depends on 11)

The method of claim 11, wherein the non-human host is a rabbit or mouse.

### Claim 14 (depends on 11)

The method of claim 11, wherein the antibodies generated in step c) are full length antibodies.

### Claim 15 (depends on 11)

The method of claim 11, wherein the antibodies generated in step c) are antibody fragments.

### Claim 16 (depends on 11)

The method of claim 11, wherein the antibodies generated in step c) are antibody derivatives.

### Claim 17 (depends on 11)

The method of claim 11, wherein the antibodies generated in step c) are fusion proteins.

### Claim 18 (depends on 11)

The method of claim 11, wherein the antibodies generated in step c) are chimerized antibodies.

### Claim 19 (depends on 18)

The method of claim 18, wherein the chimerized antibodies comprise a human Fc.

### Claim 20 (depends on 1)

The method of claim 1, wherein the B cells are B cells from a human donor.

### Claim 21 (depends on 1)

The method of claim 1, wherein the generating is generating using a biological display system to obtain a cell population displaying the antibodies.

### Claim 22 (depends on 21)

The method of claim 21, wherein d) is screening the cell population via fluorescence activated cell sorting (FACS).

### Claim 23 (depends on 21)

The method of claim 21, wherein the biological display system is a mammalian cell surface display system.

### Claim 24 (depends on 21)

The method of claim 21, wherein the biological display system is a yeast cell surface display system.

### Claim 25 (depends on 21)

The method of claim 21, wherein the biological display system is a bacterial cell surface display system.

### Claim 26 (depends on 1)

The method of claim 1, wherein the antibodies generated in step c) are full length antibodies.

### Claim 27 (depends on 1)

The method of claim 1, further comprising, after step c), obtaining the DNA sequence encoding VH and VL domains.

### Claim 28 (depends on 1)

The method of claim 1, further comprising, after step d), obtaining the DNA sequence encoding VH and VL domains.

### Claim 29 (depends on 28)

The method of claim 28, wherein obtaining the DNA sequence encoding VH and VL domains is selected from the group consisting of high-throughput sequencing, deep sequencing or combinations of the foregoing.

### Claim 30 (depends on 1)

The method of claim 1, further comprising, after step c), obtaining the DNA sequence encoding VH and VL domains, and after step d), sequencing the DNA encoding VH and VL domains.

### Claim 31 (depends on 31)

The method of claim 31, wherein obtaining the DNA sequence encoding VH and VL domains is selected from the group consisting of high-throughput sequencing, deep sequencing or combinations of the foregoing.

### Claim 32 (depends on 1)

The method of claim 1, further comprising, after step e), obtaining the DNA sequence encoding VH and VL domains.

### Claim 33 (depends on 32)

The method of claim 32, wherein obtaining the DNA sequence encoding VH and VL domains is selected from the group consisting of high-throughput sequencing, deep sequencing or combinations of the foregoing.

### Claim 34 (depends on 1)

The method of claim 1, wherein the screening step a) is a high-throughput screening.

### Claim 35 (depends on 34)

The method of claim 34, wherein the high-throughput screening is via FACS or an screening an array.

### Claim 36 (depends on 1)

The method of claim 1, The method of claim 1, wherein the screening step d) is a high-throughput screening.

### Claim 37 (depends on 36)

The method of claim 36, wherein the high-throughput screening is via FACS or an screening an array.

### Claim 38 (depends on 1)

The method of claim 1, further comprising:
e) characterizing the antibodies capable of binding to the at least one target antigen.

### Claim 39 (depends on 38)

The method of claim 38, wherein step e) comprises performing a binding assay to determine binding affinity to the target antigen.

### Claim 40 (depends on 39)

The method of claim 39, wherein the binding assay comprises an ELISA.

### Claim 41 (depends on 39)

The method of claim 39, wherein the binding affinity to the at least one target antigen is greater than 10 μM.

### Claim 42 (depends on 39)

The method of claim 39, wherein the binding affinity to the at least one target antigen is greater than 100 nM.

### Claim 43 (depends on 39)

The method of claim 39, wherein the binding affinity to the at least one target antigen is greater than 10 nM.

### Claim 44 (depends on 39)

The method of claim 39, wherein the binding affinity to the at least one target antigen is greater than 1 nM.

### Claim 45 (depends on 1)

The method of claim 1, wherein step b) comprises RT-PCR.

### Claim 46 (depends on 38)

The method of claim 38, wherein step e) comprises characterizing selected from the group consisting of determining isoelectric point, determining thermal stability, determining sedimentation rate, determining folding rate, determining neutralization of antigen activity, determining antagonistic activity, determining agonistic activity, determining expression level, determining non-specific binding, determining specificity, and determining inhibition of enzymatic activity, determining rigidity/flexibility, determining shape, determining charge, determining stability in different pH, determining stability in different solvents, determining UV stability, determining stability in different mechanical conditions, determining stability in different sonic conditions, determining half life, and determining glycosylation.

### Claim 47 (depends on 1)

The method of claim 1, further comprising evolving the recombinant antibody.

### Claim 48 (depends on 47)

The method of claim 47, where the evolving is selected from the group consisting of Comprehensive Positional Evolution, Comprehensive Positional Evolution followed by Comprehensive Protein Synthesis, random mutagenesis, and PCR shuffling.

### Claim 49 (depends on 47)

The method of claim 47, wherein the selection, evolution and expression of the antibody is in a eukaryotic cell production host; and the method comprises:
a) generating an anti-antigen antibody library in a eukaryotic cell production host;
b) screening the library for at least one predetermined property, characteristic or activity;
c) selecting a template antibody from the library;
d) evolving the template antibody to produce a set of mutant antibodies in the eukaryotic cell production host with antibody cell surface display;
e) screening the mutant antibodies for the at least one predetermined property, characteristic or activity;
f) selecting an up-mutant antibody from the set of mutant antibodies based upon optimization of the at least one predetermined property, characteristic or activity when compared to the template antibody; and
g) expressing the up-mutant antibody in the same eukaryotic cell production host as in the generating step.

### Claim 50 (depends on 49)

The method of claim 49, wherein the a) generating is generating via cell surface display.

### Claim 51 (depends on 1)

The method of claim 1, further comprising humanizing the recombinant antibody.

### Claim 52

A method of generating and identifying a recombinant antibody that binds to at least one target antigen comprising:
a) screening, via high-throughput screening, optionally comprising fluorescence activated cell sorting (FACS) or robotics, isolated B cells from a non-human host immunized with a target antigen to generate a B cell library enriched in B cells capable of binding to the target antigen;
b) amplifying cDNA obtained from mRNA expressed in the B cell library to prepare an immunoglobulin library comprising VH and VL domains;
c) generating a library of full-length antibodies from the VH and VL domains using a biological display system to obtain a cell population displaying the antibodies, whereby the antibodies comprise light chain/heavy chain combinations and whereby the number of combinations generated is more than the number of B cells in the enriched B cell library; and
d) screening via high-throughput screening, optionally comprising fluorescence activated cell sorting (FACS) or robotics, the cell population with the target antigen to identify a subset of cells displaying antibodies capable of binding to the target antigen;
whereby a recombinant antibody that binds to a target antigen is generated and identified.

### Claim 53

A method of generating and identifying a recombinant antibody that binds at least one target antigen comprising:
a) screening, via fluorescence activated cell sorting (FACS) or panning, a population of B cells from a non-human host immunized with a target antigen to generate a B cell library enriched in B cells capable of binding to the at least one target antigen;
b) amplifying cDNA obtained from mRNA expressed in a single B cell for a plurality of B cells in the B cell library to prepare an immunoglobulin library comprising VH and VL domains;
c) cloning the immunoglobulin library into an expression vector to form a library of expression vectors capable of expressing the VH and VL domains, whereby the VH and VL domains are naturally paired;
d) using the library of expression vectors to express the VH and VL domains in an expression system to form an antibody library, wherein the antibodies comprise naturally paired VH and VL domains;
e) screening the antibody library for binding to the at least one target antigen;
f) characterizing the antibodies capable of binding to the at least one target antigen,
whereby a recombinant antibody that binds at least one target antigen is generated and identified.

### Claim 54 (depends on 53)

The method of claim 53, wherein the B cell library contains at least 103 B cells.

### Claim 55 (depends on 53)

The method of claim 53, wherein the B cell library contains at least 105 B cells.

### Claim 56 (depends on 53)

The method of claim 53, wherein the B cell library contains at least 106 B cells.

### Claim 57 (depends on 53)

The method of claim 53, wherein the B cell library contains at least 107 B cells.

### Claim 58 (depends on 53)

The method of claim 53, wherein the B cell library contains at least 108 B cells.

### Claim 59 (depends on 53)

The method of claim 53, wherein the non-human host is a rabbit or mouse.

### Claim 60 (depends on 53)

The method of claim 53, further comprising, after step c), obtaining the DNA sequence encoding VH and VL domains.

### Claim 61 (depends on 53)

The method of claim 53, further comprising, after step d), obtaining the DNA sequence encoding VH and VL domains.

### Claim 62 (depends on 53)

The method of claim 53, further comprising, after step c), obtaining the DNA sequence encoding VH and VL domains, and after step d), sequencing the DNA encoding VH and VL domains.

### Claim 63 (depends on 53)

The method of claim 53, further comprising, after step e), obtaining the DNA sequence encoding VH and VL domains.

### Claim 64 (depends on 53)

The method of claim 53, wherein step e) comprises performing a binding assay to determine binding affinity to the target antigen.

### Claim 65 (depends on 64)

The method of claim 64, wherein the binding assay comprises an ELISA.

### Claim 66 (depends on 64)

The method of claim 64, wherein the binding affinity to the at least one target antigen is greater than 10 μM.

### Claim 67 (depends on 64)

The method of claim 64, wherein the binding affinity to the at least one target antigen is greater than 100 nM.

### Claim 68 (depends on 64)

The method of claim 64, wherein the binding affinity to the at least one target antigen is greater than 10 nM.

### Claim 69 (depends on 64)

The method of claim 64, wherein the binding affinity to the at least one target antigen is greater than 1 nM.

### Claim 70 (depends on 53)

The method of claim 53, wherein step b) comprises RT-PCR.

### Claim 71 (depends on 53)

The method of claim 53, wherein step e) comprises characterizing selected from the group consisting of determining isoelectric point, determining thermal stability, determining sedimentation rate, determining folding rate, determining neutralization of antigen activity, determining antagonistic activity, determining agonistic activity, determining expression level, determining non-specific binding, determining specificity, and determining inhibition of enzymatic activity, determining rigidity/flexibility, determining shape, determining charge, determining stability in different pH, determining stability in different solvents, determining s UV stability, determining stability in different mechanical conditions, determining stability in different sonic conditions, determining half life, and determining glycosylation.

### Claim 72

A method of generating and identifying a recombinant antibody that binds at least one target antigen comprising:
a) screening B cells to generate a B cell library enriched in B cells capable of binding to the at least one target antigen;
b) amplifying cDNA obtained from mRNA expressed in the B cell library to prepare an immunoglobulin library comprising VH domains;
c) generating antibodies from the VH domains and at least one VL domain from another source, whereby the antibodies comprise light chain/heavy chain combinations; and
d) screening the antibodies with the target antigen to identify a subset of antibodies capable of binding to the at least one target antigen.
